Dr. Ashish Joshi

Dr. Ashish Joshi

Oncology

MD (Internal Medicine), DM (Medical Oncology), Advanced Certification in Molecular Oncology

Profile

Dr. Ashish Joshi is associated with Lilavati Hospital as a Consultant, Medical Oncologist. With 14 years of successful community oncology practice in the Western suburbs of Mumbai, he has demonstrated excellence in providing innovative, evidence-based medical oncology care to cancer patients. He has collaborated closely with multidisciplinary teams to ensure optimal patient outcomes and actively participated in clinical trials and research studies. Dr. Joshi has a keen interest in creating innovations in oncology and enhancing scientific research focusing on Indian data. He created and executed a groundbreaking healthcare model of daycare oncology centers across India and developed clinical strategies for the diagnosis, treatment, and follow-up of cancer patients, with a focus on medical oncology care. His expertise includes Molecular Oncology, Precision Medicine, and Immunotherapy.

Awards and Recognition
  • Gold Medal at DM Medical Oncology Examination, Gujarat University, August 2011
  • Best Case Presentation, ICON, New Delhi, August 2011
  • 1st prize in Leukemia quiz at the national level conference, Mumbai Hematology Association, December 2010
  • Founding Director of India’s largest day-care oncology chain, MOC (Mumbai Oncocare Centre), January 2018
  • Key Founder of the Research Wing at MOC; Currently Principal Investigator for 18 clinical trials and Co-Investigator for 7 clinical trials, July 2023
Research Publications
  • "Use of atorvastatin and atorvastatin and Isapgul combination in the treatment of dyslipidemia in non-diabetic population", Journal of the Indian Medical Association, Vol. 105, No 03, March 2007, pp 142-145
  • "Dasatinib-Induced Lymphocytosis and Pleural Effusion in a Patient of Chronic Myeloid Leukemia: A Rare Indian Case Report", Indian Journal of Medical and Paediatric Oncology, Volume 41, Issue 3, May-June 2020
  • "The clinical utility and safety of Short Course Immune checkpoint inhibitors (ICI) in multiple tumors - A real world multicentric study from India", International Journal of Cancer, 09 November 2021
  • "NSCLC: Real-world data analysis from a chain of oncology centres in Western India", Published in Annals of Oncology
  • "A Real World Molecular Epidemiological Study of Non-Small-Cell Lung Cancer (NSCLC) Patients from Western India", Accepted in South Asian Journal of Cancer
  • "Disease features and Treatment Patterns in patients with Polycythemia Vera in India: Real-world evidence", Accepted in South Asian Journal of Cancer
  • "Disease features and treatment patterns in patients with advanced prostate cancer progressing to metastatic castration-resistant prostate cancer in India: Real-world evidence", Accepted in South Asian Journal of Cancer
Poster Ad